19th IDS Congress
Paris 2023
23-27 May. 2023
The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving understanding and treatment of type 1 diabetes. IDS organizes a Congress every 18 months in major centres in Europe, North America and Asia/Oceania at which there are scientific presentations to further this goal.
Centre international de Conférences Sorbonne Université
4 place Jussieu - 44-55
75005 - Paris, France
*To submit before 15th February 2023
Confirmed Speakers
(by alphabetical order)
Peter Achenbach, Mark Atkinson, Jean-François Bach, Burkhard Becher, Polly Bingley, Christian Boitard, Ezio Enrico Bonifacio, Marcela Brissova, Todd Brusko, Jenny Couper, Mark M. Davis, Gerard Eberl, Decio L. Eizirik, Donna Farber, Carla Greenbaum, John Harris, Len Harrisson, Matthias Hebrok, Kevan Herold, Heikki Hyoty, Sally Kent, David Klatzmann, Aaron J. Kowalski, Jeffrey Krischer, Vito Lampasona, Peter E. Lipsky, Chantal Mathieu, Eoin McKinney, Gerald T. Nepom, Maria Cristina Nostro, Timo Otonkoski, Alberto Pugliese, Frédéric Rieux-Laucat, Bart Roep, Miguel Sanjuan, Pere Santamaria, Andrea Schietinger, Anath Shalev, Tommi Suvitaival, Qizhi Tang, Timothy Tree, Tommi Vatanen, Carola Vinuesa, John Wentworth, Benjamin Youngblood, Anette Ziegler
Thursday 25th
8.20 am
Plenary 3
Stem-like autoimmune CD8+ T cells: Andrea Schietinger (Sloan Kettering, New York)
9.00 am
Short Symposium 3: Theme to be defined
Talk 15
Talk 16
Oral Abstract 13
Oral Abstract 14
Oral Abstract 15
11.00 am
Short Symposium 4: Fresh ideas from early researchers, session led by PhD candidates/Postdoc scientists – Coordinators: Alice Long, Teresa Rodriguez-Calvo
*3 puzzling findings that we would like to understand
*3 outstanding questions that we would like to see addressed in T1D research, and how
12.00 - 1.30 pm
9.00 - 10.30 am
Parallel session: Editorial tips in academic publishing
Jennifer Sargent, Deputy Editor Nature Medicine
Marta Koch, Editor-in-Chief Lancet Diabetes Endocrinology
10.30 - 11 am
Break
Parallel session : Improving the design of clinical trials in T1D: analysis of data from the Trial Outcome Markers Initiative (TOMI) collaboration - Room 109, barre 44-54, 1st floor.
The Trial Outcome Marker Initiative (TOMI) brings together data from >10,000 individuals with new-onset T1D including 2,900 from 21 different clinical trials. Analysis of C-peptide, HbA1c and composite outcomes will be discussed, which has provided significant insights into designing clinical trials for stage 3 T1D
1.00 - 2.00 pm
Lunch
2.00 pm
4.30 - 5.00 pm
Break
IDS General Assembly
5.00 pm
2.30 pm
Consortia roundtable, “pulling it all together”: 3 things we have learned / we expect to learn from other consortia – synergies and opportunities
nPOD (A. Pugliese), INNODIA (C. Matthieu), TrialNet (K. Herold), ITN (J. Nepom), ENDIA (J. Couper), GPPAD (A. Ziegler), TEDDY (J. Krischer).
6.30 pm
Long Symposium 4: Common themes in autoimmunity
Talk 17: Autoimmune heterogeneity and gene variants: Carola Vinuesa (Francis Crick Institute, London)
Talk 18: Vitiligo: John Harris (Umass, Worchester)
Talk 19: Immune and target cell cross-talk in autoimmune diseases: Decio Eizirik (ULB, Brussels)
Talk 20: Drug repurpusing in autoimmune diseases: Peter Lipsky (Ampel Biosolutions, Charlottesville)
Oral Abstract 16